Get the Stockscreener App
7.46
0.27%
0.02
Pre-market:
7.44
-0.02
-0.27%
Kamada Ltd stock is traded at $7.46, with a volume of 18,648.
It is up +0.27% in the last 24 hours and down -3.24% over the past month.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
See More
Previous Close:
$7.44
Open:
$7.48
24h Volume:
18,648
Relative Volume:
0.34
Market Cap:
$430.34M
Revenue:
$181.68M
Net Income/Loss:
$20.37M
P/E Ratio:
21.34
EPS:
0.3495
Net Cash Flow:
$17.31M
1W Performance:
+3.04%
1M Performance:
-3.24%
6M Performance:
+2.90%
1Y Performance:
+8.43%
1-Day Range:
$7.45
$7.52
1-Week Range:
$7.085
$7.52
52-Week Range:
$6.50
$9.35
Kamada Ltd Stock (KMDA) Company Profile
Compare KMDA vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KMDA
Kamada Ltd
|
7.46 | 430.34M | 181.68M | 20.37M | 17.31M | 0.3495 |
TAK
Takeda Pharmaceutical Co Adr
|
15.77 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.07 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.69 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.95 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.57 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Kamada Ltd Stock (KMDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | The Benchmark Company | Buy |
| Jul-03-24 | Initiated | Stifel | Buy |
| Feb-02-18 | Initiated | Chardan Capital Markets | Buy |
Kamada Ltd Stock (KMDA) Latest News
Goalscorer Kamada credits ex-Palace boss Glasner for his Japan turnaround - The Japan Times
Daichi Kamada steals a point - The Financial Express
Crystal Palace at World Cup: Daichi Kamada reacts to ‘lucky’ equaliser vs Netherlands - Read Crystal Palace
How Kamada became Japan’s unlikely hero in World Cup classic vs Netherlands - The Indian Express
Japan vs Netherlands FIFA World Cup Match Result: Kamada's 88th-minute heroics rescue Japan in dramatic d - The Times of India
Daichi Kamada’s Late Header Gives Japan a 2-2 Draw with the Netherlands in World Cup Opener for Both - Kiripost
World Cup 2026: Kamada’s late header snatches draw for Japan against Netherlands - Business News Nigeria
Netherlands vs Japan highlights: Daichi Kamada’s late equalizer rescues Samurai Blue in FIFA World Cup th - The Times of India
Japan vs Netherlands: Kamada's Late Goal Secures 2-2 Draw - The News Mill
Kamada’s Late Header Earns Japan Thrilling 2-2 Draw Against Netherlands - NewsGhana
FIFA World Cup 2026: Late Kamada goal gives Japan point against NetherlandsNED vs JAP player ratings - Sportstar
KMDA Q1 2026 Earnings: EPS Misses Estimates Amid Operational ChallengesNext Quarter Guidance - newsline.com
KMDA Q1 2026 Earnings: EPS Misses Estimates Amid Revenue Disclosure GapRevenue Surprise History - newsline.com
Kamada (KMDA) Q1 2026 Earnings: EPS Misses Estimates, Stock DeclinesGuidance Accuracy Score - newsline.com
Why Is Kamada Ltd. (KMDA) Stock Down Today? - Meyka
KMDA Q1 2026 Earnings: EPS Misses Estimates as Stock Slips -2.85%Forward Guidance Trends - newsline.com
KMDA News | KAMADA LTD (NASDAQ:KMDA) - ChartMill
Kamada: Undervalued, Yet Execution Risks Keep It A Hold (NASDAQ:KMDA) - Seeking Alpha
Kamada gets FDA approval for Rapid Fluorescent Focus Inhibition Test laboratory - TipRanks
Kamada (KMDA) Receives FDA Nod for New Fluorescent Focus Inhibition Test - GuruFocus
Kamada receives FDA approval for rabies antibody testing lab By Investing.com - Investing.com Australia
Kamada receives FDA approval for rabies antibody testing lab - Investing.com
Kamada Receives FDA Approval for In-House Rabies Virus Neutralization Testing Laboratory - geneonline.com
Kamada Wins FDA Nod for New In‑House Rabies Antibody Testing Lab - TipRanks
Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory - The Manila Times
Kamada (KMDA) wins FDA approval for in-house RFFIT rabies antibody testing lab - Stock Titan
Kamada (KMDA) Slides 0.64% as Price Tests Key Support Zone Near $7.42Sign of Weakness - The Legal Advocate
Kamada Ltd. (KMDA) Holds Steady Near Support as Trading Volume Remains ModerateRTH Profile - newsline.com
Kamada Ltd stock (IL0010952647): shares stabilize after recent results as investors eye valuation me - AD HOC NEWS
Kamada Ltd. (KMDA) Climbs 1.66% as Shares Approach Key Resistance at $8.36Jurik MA - The Legal Advocate
KMDA Q1 2026 Earnings: EPS Misses Estimates Despite Positive Stock ReactionOperating Margin Analysis - The Legal Advocate
Kamada Q1 earnings call highlights - MSN
KMDA Insider Transactions: Officers & Directors File Initial Holdings, May 21, 2026 - Meyka
Kamada Ltd Earnings Call Balances Growth And Risks - The Globe and Mail
Benchmark reiterates Kamada stock Buy rating after Q1 miss By Investing.com - Investing.com Australia
Benchmark reiterates Kamada stock Buy rating after Q1 miss - Investing.com
KMDA Kamada shares rise 351 on strong 121 revenue growth despite EPS missEvent Driven - Newser
Kamada Ltd stock (IL0010952647): biotech shares in focus after recent quarterly update - AD HOC NEWS
Kamada Ltd stock (IL0010952647): plasma?derived therapies under the spotlight after recent updates - AD HOC NEWS
H.C. Wainwright reiterates Kamada stock rating on guidance outlook - Investing.com UK
Kamada Ltd. (NASDAQ:KMDA) Q1 2026 Earnings Call Transcript - Insider Monkey
H.C. Wainwright reiterates Kamada stock rating on guidance outlook By Investing.com - Investing.com Australia
Kamada Ltd (KMDA) Q1 2026 Earnings Call Highlights: Strategic Gr - GuruFocus
Kamada Ltd.Ordinary Shares (NQ: KMDA - FinancialContent
Kamada Falls Short on Q1 2026: $0.07 EPS vs $0.12 Expected - AlphaStreet
Kamada reports Q1 EPS 7c, consensus 12c - TipRanks
Kamada Ltd Stock (KMDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
9.24%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):